MONET1-MOtesanib NSCLC Efficacy and Tolerability Study


Tracking Information

Start Date  ICMJEJuly 2007
Estimated Primary Completion DateMarch 2013   (final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 6, 2008)
Overall survival time. Time from randomization to death. Subjects who have not died while on study or are lost to follow up will be censored at their last contact date. [ Time Frame: Not able to be measured ] [ Designated as safety issue: No ]
Original Primary Outcome Measures ICMJE 
 (submitted: April 12, 2007)
Overall survival time. Time from randomization to death. Subjects who have not died while on study or are lost to follow up will be censored at their last contact date.
Change HistoryComplete list of historical versions of study NCT00460317 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ICMJE 
 (submitted: March 6, 2008)
  • Progression free survival time: . Subjects who have not progressed or died on study will be censored at their last evaluable assessment date. [ Time Frame: Time from randomization to objective disease progression or death due to any cause ] [ Designated as safety issue: No ]
  • Objective tumour response rate (complete and partial response) according to modified RECIST criteria in subjects with measurable disease at baseline. [ Designated as safety issue: No ]
  • Duration of response (calculated for only those subjects who respond): [ Time Frame: Time from first objective tumour response to objective disease progression or death due to any cause. ] [ Designated as safety issue: No ]
  • Pharmacokinetics of AMG 706 when administered in combination with paclitaxel and carboplatin. [ Time Frame: throughout the duration the patient is in the study. ] [ Designated as safety issue: No ]
Original Secondary Outcome Measures ICMJE 
 (submitted: April 12, 2007)
  • Progression free survival time: Time from randomization to objective disease progression or death due to any cause. Subjects who have not progressed or died on study will be censored at their last evaluable assessment date.
  • Objective tumour response rate (complete and partial response) according to modified RECIST criteria in subjects with measurable disease at baseline.
  • Duration of response (calculated for only those subjects who respond): Time from first objective tumour response to objective disease progression or death due to any cause.
  • Pharmacokinetics of AMG 706 when administered in combination with paclitaxel and carboplatin.

Descriptive Information

Brief Title  ICMJEMONET1-MOtesanib NSCLC Efficacy and Tolerability Study
Official Title  ICMJEA Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer.
Brief Summary

To determine if treatment with AMG 706 in combination with paclitaxel and carboplatin improves overall survival compared to treatment with placebo in combination with paclitaxel and carboplatin in subjects with advanced non-squamous NSCLC and in subjects with adenocarcinoma histology (adenocarcinoma subpopulation).

Detailed Description 
Study PhasePhase III
Study Type  ICMJEInterventional
Study Design  ICMJETreatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study
Condition  ICMJENon-small Cell Lung Cancer
Intervention  ICMJE
  • Drug: AMG 706
    125 mg QD orally every day
  • Drug: placebo
    125 mg QD orally every day
Study Arms / Comparison Groups
  • Arm B: Placebo Comparator
    All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and placebo 125mg QD orally
    Intervention: Drug: placebo
  • Arm A: Active Comparator
    All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and AMG 706 125mg QD orally.
    Intervention: Drug: AMG 706

Recruitment Information

Estimated Enrollment  ICMJE1400
Estimated Completion DateJuly 2013
Estimated Primary Completion DateMarch 2013   (final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologically confirmed, unresectable stage 111B with pericardial or pleural effusion or stage IV or recurrent non squamous NSCLC.
  • Measurable or non-measurable disease per modified RECIST criteria
  • ECOG performance status of 0 or 1
  • Life expectancy of greater than or equal to 3 months as documented by the investigator
  • ability to take oral medications
  • competency to give written informed consent
  • able to start protocol directed therapy within 7 days from date of randomization
  • Hematological function, as follows:
  • Absolute neutrophil count (ANC) > = 1.5 x 109/L
  • Platelet count > = 100 x 109/L and < = 850 x 109/L
  • Hemoglobin > =9 g/dL
  • Renal function, as follows:
  • Creatinine clearance > 40 mL/min (calculated by Cockcroft Gault formula)
  • Urinary protein quantitative value of < = 30 mg in urinalysis or < = 1+ on dipstick unless quantitative protein is < 500 mg in a 24 hour urine sample
  • Hepatic function, as follows:
  • Aspartate aminotransferase (AST) < =2.5 x upper limit of normal (ULN) OR AST < 5 x ULN if liver metastases are present
  • Alanine aminotransferase (ALT) < =2.5 x ULN OR ALT < 5 x ULN if liver metastases are present
  • Alkaline phosphatase < = 2.0 x ULN OR alkaline phosphatase < 5 x ULN if liver or bone metastases are present
  • Total bilirubin < 1.5 x ULN OR total bilirubin < 3 X ULN if subject has UGT1A1 promoter polymorphism (ie, Gilbert syndrome) confirmed by genotyping or Invader UGT1A1 Molecular Assay prior to randomization Partial thromboplastin (PTT) or activated partial thromboplastin time (aPTT) < = 1 x ULN and international normalized ratio (INR) < = 1.5 x ULN

Exclusion Criteria:

  • Subjects with adenosquamous histology or an unclear histology subtype (eg, not otherwise specified) containing greater than 10% squamous cells
  • untreated or symptomatic central nervous system metastases. Subjects with a history of brain metastases are eligible if definitive therapy has been administered (surgery and/or radiation therapy), there is no planned treatment for brain metastases, and the subject is clinically stable and is off corticosteroids for at least 2 weeks prior to randomization.
  • Prior chemotherapy as follows: Any prior chemotherapy for advanced non squamous NSCLC
  • Any prior adjuvant chemotherapy for non squamous NSCLC within 52 weeks prior to randomization. Adjuvant chemotherapy completed > 52 weeks prior to randomization is permitted. Any prior chemoradiation for locally advanced stage III disease.
  • Prior (within 30 days of randomization) yellow fever vaccination.
  • Central (chest) radiation therapy within 28 days prior to randomization, radiation therapy within 14 days prior to randomization for peripheral lesions.
  • History of pulmonary hemorrhage or gross hemoptysis (approximately 3 mL of bright red blood or more) within 6 months prior to randomization.
  • Prior targeted therapies, including but not limited to:
  • AMG 706, inhibitors of VEGF (eg, SU5416, SU6668, ZD6474, SU11248, PTK787, AZD2171, AEE 788, sorafenib, bevacizumab), or EGFr (eg, panitumumab, cetuximab, gefitinib, erlotinib).
  • Known history of allergy or hypersensitivity reaction to paclitaxel or carboplatin.
  • Any anticoagulation therapy within 7 days prior to randomization. The use of low-dose warfarin [ < = 2 mg daily] or low molecular weight heparin or heparin flushes for prophylaxis against central venous catheter thrombosis is allowed.
  • History of arterial or venous thrombosis within 12 months prior to randomization.
  • History of bleeding diathesis or bleeding within 14 days prior to randomization.
  • Peripheral neuropathy > grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.
  • Clinically significant cardiac disease within 12 months of randomization, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, percutaneous transluminal coronary angioplasty/stent, congestive heart failure, or ongoing arrhythmias requiring medication.
  • History of other primary cancer unless: Curatively resected non melanomatous skin cancer. Curatively treated cervical carcinoma in situ. Other primary solid tumor curatively treated with no known active disease present and no curative treatment administered for the last 3 years
  • Any kind of disorder that compromises the ability of the subject to comply with the study procedures.
  • Open wound, ulcer or fracture.
  • Uncontrolled hypertension as defined by resting blood pressure > 150/90 mm Hg. Antihypertensive medications are allowed if the subject is stable on their current dose at the time of randomization.
  • Surgery:
  • Major surgical procedures within 28 days prior to randomization
  • Minor surgical procedures within 14 days prior to randomization
  • Failure to recover from prior surgery
  • Placement of a central venous access device (including ports and tunneled or non-tunneled catheters) within 7 days prior to randomization
  • Planned elective surgery while on study treatment
  • Core needle biopsy within 7 days prior to randomization
  • Not recovered from all previous therapies (ie, radiation, surgery and medications). Adverse events related to previous therapies must be CTCAE grade < = 1 at screening or returned to the subject's baseline prior to their most recent previous therapy.
  • Participation in therapeutic clinical trials or currently receiving other investigational treatment(s) within 30 days prior to randomization.
  • Pregnant (eg, positive HCG test-serum or urine) or breast feeding woman.
  • Any subject not consenting to use adequate contraceptive precautions (eg, hormonal, barrier or abstinence) during the course of the study and for 6 months after the last treatment.
  • Known to be human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C positive.
  • Known chronic hepatitis.
  • Active infection requiring systemic treatment or any uncontrolled infection < = 14 days prior to randomization.
  • History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risks associated with the study participation or investigational product(s) administration or may interfere with the interpretation of the results.
  • Previously randomized to this study.
  • Not available for follow-up assessments or unable to comply with study requirements.
GenderBoth
Ages18 Years and older
Accepts Healthy VolunteersNo
Contacts  ICMJE
Contact: Amgen Call Center866-572-6436
Location Countries  ICMJEUnited States,   Argentina,   Australia,   Austria,   Brazil,   Bulgaria,   Canada,   Chile,   Czech Republic,   France,   Germany,   Greece,   Hong Kong,   Hungary,   India,   Ireland,   Italy,   Japan,   Korea, Republic of,   Mexico,   New Zealand,   Philippines,   Poland,   Romania,   Russian Federation,   Singapore,   Slovakia,   Spain,   Taiwan,   Turkey,   Ukraine,   United Kingdom

Administrative Information

NCT ID  ICMJENCT00460317
Responsible PartyGlobal Development Leader, Amgen Inc.
Study ID Numbers  ICMJE20050201
Study Sponsor  ICMJEAmgen
Collaborators  ICMJETakeda Global Research & Development Center, Inc.
Investigators  ICMJE
Study Director:MDAmgen
Information Provided ByAmgen